[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592104":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":31,"locations":37,"responsibleParty":55,"collaborators":57,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":24,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":24,"enrollmentInfo":73,"targetDuration":24,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":39,"whyStopped":24,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Virginia Commonwealth University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fearless Immediate Treatment Arm","EXPERIMENTAL","FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions. FearLess will be delivered immediately following enrollment in this arm.",[13],"Behavioral: Fearless in Neuro-Oncology",{"label":15,"type":6,"description":16,"interventionNames":17},"FearLess Delayed Control Arm","FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions. In this arm, the FearLess intervention will begin following a 12-week no-treatment period.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BEHAVIORAL","Fearless in Neuro-Oncology","FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions.",[15,9],null,[26,29],{"name":27,"affiliation":5,"role":28},"Ashlee R Loughan, Ph.D","PRINCIPAL_INVESTIGATOR",{"name":30,"affiliation":5,"role":28},"Sarah E Braun, Ph.D.",[32],{"name":33,"role":34,"phone":35,"phoneExt":24,"email":36},"Mary Bridgman","CONTACT","804-628-6799","LiveNOW@vcu.edu",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Richmond","Virginia","23298","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-77.46026,37.55376,{"lat":49,"lon":48},[52],{"name":53,"role":34,"phone":24,"phoneExt":24,"email":54},"Ashlee Loughan, PhD","ashlee.loughan@vcuhealth.org",{"type":56,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[58,61],{"name":59,"class":60},"National Cancer Institute (NCI)","NIH",{"name":62,"class":63},"National Brain Tumor Society","UNKNOWN","100592104","fearless-in-neurooncology-100592104",false,"NCT06989086","FearLess in NeuroOncology","FearLess in Neuro-Oncology","Inclusion Criteria:\n\nPatients:\n\n* Self-report a diagnosis of a primary malignant brain tumor (grade II-IV)\n* \\>2 weeks post-cranial resection or biopsy\n* Elevated Fear of Recurrence Distress Rating\n* Primarily English speaking\n* \\>\u002F= 18 years of age at the time of enrollment\n\nCaregivers:\n\n* nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV)\n* Elevated Fear of Recurrence Distress Rating\n* Primarily English speaking\n* \\>\u002F= 18 years of age at the time of enrollment\n\nExclusion Criteria:\n\nPatient \u002F Caregiver Exclusion:\n\n* Cognitive impairment that might prohibit active intervention engagement\n* Inability to understand and provide informed consent\n* Inability to attend virtual sessions due to unstable or no internet connection","ALL","18 Years",{"count":74,"type":75},112,"ESTIMATED","INTERVENTIONAL",[78],"NA","The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers",[81,82,83,84,85],"Primary Malignant Brain Tumor","Glioblastoma (GBM)","Astrocytoma","Oligodendroglioma","Caregiver",[87],"brain tumor","2025-09-02",{"date":90,"type":91},"2025-09-09","ACTUAL",{"date":93,"type":91},"2025-06-24",{"date":95,"type":75},"2028-12-31",{"name":5,"class":6},1]